Arrowhead Research | ARWR - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
Alnylam Pharmaceuticals USD 1.06B 160.97M 2026-06
Anika Therapeutics USD 137.28M 3.38M 2026-06
Arrowhead Research USD 245.35M 30.35M 2026-06
Heron Therapeutics USD 40.55M 1.46M 2025-12
Incyte USD 973.64M 4.65B 2026-06
Ionis Pharmaceuticals USD 370.24M 6.24M 2026-06
Ligand Pharmaceuticals USD 55.1M 20.75M 2026-06
Merck USD 15.77B 2.4B 2026-06
Moderna USD 960M 817M 2026-06
Nektar Therapeutics USD 49.12M 8.22M 2026-03
Novartis USD 10.2B 912M 2026-06
Sarepta Therapeutics USD 387.96M 15.59M 2026-06
TG Therapeutics USD 218.66M 48.54M 2026-06
Ultragenyx Pharmaceutical USD 289M 16M 2026-06
Vertex Pharmaceuticals USD 2.07B 217.1M 2026-06
Xencor USD 87.82M 5.44M 2026-06